instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
The vaccine, developed by U.S. drugmaker Merck & Co, is already being used under emergency guidelines to try to protect people against the spread of a deadly Ebola outbreak in Democratic Republic of Congo. It protects against the Zaire strain of the Ebola virus - the one that most commonly causes outbreaks. The shot is also being reviewed under a fast-track system by regulators in the United States, with a decision expected in the first quarter of next year. "This vaccine has already saved many lives in the current Ebola outbreak, and the decision by European regulators will help it to eventually save many more," the WHO's director-general Tedros Adhanom Ghebreyesus said in a statement. The Congo Ebola outbreak has killed more than 2,100 people since the middle of last year. It is the second-largest Ebola outbreak in history, after a 2013-16 epidemic in West Africa that killed more than 11,300. The Merck vaccine, which the company has now brand-named Ervebo, is likely to get a full marketing license from the European Commission in a few weeks. Roger Perlmutter, president of Merck Research Laboratories, said the company's priority now was to get regulatory approval of its Ervebo manufacturing site in Germany so that licensed supply of the vaccine "can be used to support global public health preparedness". Merck's vaccine is being used in Congo in a so-called "ring vaccination" approach, in which people who may have been in contact with someone newly infected with Ebola are traced and offered the shot to protect them. Charlie Weller, head of vaccines at the Wellcome Trust global heath charity said the Merck shot had already saved "countless lives" in the country. "Having this vaccine available under research conditions has been key in preventing the ongoing outbreak in the DRC spiraling into a repeat of the 2014-16 epidemic, where 11,000 people died," she told Reuters. Health authorities in Kinshasa said last week they planned to introduce an experimental second Ebola vaccine, developed by drugmaker Johnson & Johnson, in the country's eastern provinces in November. The Ebola virus causes hemorrhagic fever and spreads from person to person through direct contact with body fluids. It kills around half of those it infects. There are currently no licensed treatments for the deadly infection, but scientists said in August they were a step closer to being able to cure it after two experimental drugs showed survival rates of as much as 90% in a clinical trial in Congo.
answer:
This is a photograph of a letter from C. Dennis Packee of Reiman's Harley-Davidson in Kewanee, Ill., to Christopher and Jamie Walters. The letter explains that Reiman's will store the Walters' motorcycles at no charge. It is their way of saying thank you to military members on deployment.

question:
"The story provides the cost of the CT scan as well as angiography. However, the story should have discussed insurance coverage for the scans. The story describes the percentage of patients with blockages that were identified with either the CT scan or the angiogram. The story should have also described the probability of having blockages with a positive scan (positive predictive value). This is the more important piece of information to a consumer. Also not described in the story is whether the CT scans had any impact at all on downstream outcomes, such as heart attacks, deaths, or procedures. The story correctly describes radiation exposure as one of the harms of the heart CT. The story could have described other harms, such as theimplications offalse positive or false negativetest results. The story adequately describes the design of the current study, including a criticism from one expert that the study ""cherry-picked"" patients to include in the study in order to maximize the findings. The story does not exaggerate the seriousness or prevalence of heart disease. However, the story could have been more clear about who the CT scans are intended for. The study in question was in those with suspected heart disease, not the assymptomatic or ""worried well"". The use of CT scans in the larger asymptomatic population is controversial. The story quotes multiple independent experts who provide valuable commentary on the implications of the new findings. The story mentions angiography as the alternative to the heart CT. The story clearly states that the CT scans are relatively new and available in many hospitals, however it is not clear how many hospitals have purchased these machines. The story adequately describes the novelty of the scans. Because the story quotes multiple experts, the reader can assume that the story did not rely on a press release as the sole source of information."
answer:
'Super X-rays' show promise for finding heart disease but produce high radiation dose

question:
Biotechnology company Alkermes said earlier in the day that it expected Lilly to drop out of their program to develop an inhaled insulin treatment for diabetes, sending Alkermes shares down more than 9 percent. Lilly's decision marks the third setback in recent months for inhaled insulin formulations, once deemed potential blockbuster products because of their greater convenience than standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the alcohol addiction drug Vivitrol, said Lilly has the right to terminate its license to the inhaled treatment, Air Insulin, at its discretion. "While Lilly may elect not to commercialize Air Insulin, Alkermes believes that the phase 3 safety and efficacy trials should be completed," Alkermes said in a statement. After Lilly's announcement, the company said it was evaluating the impact of the termination, which will become effective in 90 days. Indianapolis-based Lilly said its decision was not due to safety concerns, "but rather was a result of increasing uncertainties in the regulatory environment, and a thorough evaluation of the evolving commercial and clinical potential of the product compared to existing medical therapies." Lilly Chief Operating Officer John Lechleiter said in a statement that the company is beginning the process of halting ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of around $90 million to $120 million, or 5 cents to 7 cents per share. The company said its adjusted earnings per share outlook remains unchanged at $3.85 to $4.00, while net earnings will range from $3.73 to $3.90. Lilly's action comes just five months after Pfizer Inc abandoned Exubera, the first approved inhaled form of insulin, and returned rights to the product to longtime partner Nektar Therapeutics. Exubera had dismal sales because patients were turned off by the clumsy device used to administer the powdered insulin and because doctors were concerned by the drug's tendency to slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with Reuters in October, said Air Insulin may have similar effects on lung function. "We're assuming that pulmonary insulins in that regard are all pretty much the same," he said, although a conclusive picture of Air Insulin's safety will not emerge until two-year safety trials of the product end later this year. A second setback for inhaled insulin came in January, when Novo Nordisk said it was halting development of its AERx product, meant to deliver inhaled droplets. The Danish drugmaker said AERx did not have adequate sales potential, given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly's abandonment of AIR Insulin made good business sense. "We are not (at) all surprised, and have never been strong advocates of the pulmonary insulin agents, following the poor launch and ultimate demise of Pfizer and Nektar's Exubera and Novo Nordisk's termination of its AERx program," Rubin said in a research note. Rubin said Alkermes, known for its drug-delivery technology, is unlikely to continue development of Air Insulin without Lilly, "given that this represents the third termination of a pulmonary insulin drug." But she said the sharp drop in Alkermes shares represented a buying opportunity for investors because Air Insulin had only paltry sales potential. She said investors should be focused instead on another product Alkermes is developing with Lilly: a long-acting formulation of Lilly's Byetta diabetes treatment called Byetta "We estimate that Byetta LAR could be worth $11 to $12 for the (Alkermes) stock," Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling products, rose 2 cents to end at $49.70 on the New York Stock Exchange, and was slightly lower at $49.67 in after-hours trading.
answer:
Eli Lilly drops inhaled insulin program.